

**Technical Working Party for Vegetables****TWV/58/3 Add.****Fifty-Eighth Session  
Virtual meeting, April 22 to 25, 2024****Original:** English  
**Date:** April 22, 2024

---

**ADDENDUM TO:  
ASSESSING DISTINCTNESS IN DISEASE RESISTANCE CHARACTERISTICS**

*Document prepared by experts from France and the Netherlands (Kingdom of the), with the support of European Union, Japan and breeders' organizations*

*Disclaimer: this document does not represent UPOV policies or guidance*

The annex to this document contains a copy of a presentation "Disease resistance characteristics /states of expressions / applied scales", to be made by experts from France and the Netherlands (Kingdom of the), with the support of European Union, Japan and breeders' organizations, at the fifty-eighth session of the Technical Working Party for Vegetables (TWV).

[Annex follows]

## TWV 2024

# Disease resistance characteristics /states of expressions / applied scales

### *Background of the discussion*

## TWV/57/26 Corr.\_TWV 2023 Report

23. The TWV agreed there were certain quantitative (QN) disease resistance characteristics where it was not possible to describe different levels of resistance according to QN states of expression because of the influence of testing conditions and the lack of information on genetic background.

24. The TWV agreed to invite the experts from France and the Netherlands, with the support of the European Union, Japan and the breeders' organizations, to draft a proposal for a special type of quantitative disease resistance characteristic with only two states of expression. The TWV agreed that the proposal with an explanation on the criteria for using this type of characteristic should be presented at the fifty-eighth session of the TWV.

1

## Present situations

It is defined by a least **3 founding UPOV documents** :

- TG/1/3
- TGP/7/9
- TGP/12

2

TG/1/3 General Introduction  
CHAPTER 4 – CHARACTERISTICS USED IN DUS TESTING.

4.4 Types of Expression of Characteristics

4.4.1	<i>Qualitative Characteristics</i> .....	10
4.4.2	<i>Quantitative Characteristics</i> .....	10
4.4.3	<i>Pseudo-Qualitative Characteristics</i> .....	10

3

TGP/7/9 DEVELOPMENT OF TEST GUIDELINES Annex 3 Guidance notes  
GN 20: Presentation of characteristics: States of expression  
according to type of expression of a characteristic

1.	<i>Introduction</i> .....	57
2.	<i>Qualitative characteristics</i> .....	57
	2.1 Explanation .....	57
	2.2 Separating Qualitative Characteristics .....	57
	2.3 Division of Range of Expression into States and Notes .....	58
3.	<i>Quantitative characteristics</i> .....	58
	3.1 Explanation .....	58
	3.2 Division of Range of Expression into States and Notes .....	58
	3.3 The "1-9" scale .....	59
	3.4 "Limited" range 1-5 scale .....	61
	3.5 The "1-3" scale .....	61
	3.6 The "1-4" scale .....	62
	3.7 The ">9" scale .....	62
	3.8 Wording of States .....	63
	3.9 Color .....	63
4.	<i>Pseudo-Qualitative characteristics</i> .....	63
	4.1 Explanation .....	63
	4.2 Division of Range of Expression into States and Notes .....	63
	4.3 Individual and Combined States of Expression .....	64
	4.4 Color .....	64
	4.5 Shape .....	64

4

## TGP/12/4 Guidance on Certain Physiological Characteristics

### SECTION I: DEVELOPMENT OF CHARACTERISTICS BASED ON A RESPONSE TO AN EXTERNAL FACTOR

## 2. DISEASE RESISTANCE

2.1	Introduction .....	5
2.2	Criteria for use of disease resistance characteristics .....	5
2.2.1	Results from a given genotype or combination of genotypes (see Table 1 (a)).....	5
2.2.2	Is sufficiently consistent and repeatable in a particular environment (see Table 1 (b)) .....	6
2.2.3	Exhibits sufficient variation between varieties to be able to establish distinctness (see Table 1 (c)).....	6
2.2.4	Is capable of precise definition and recognition (see Table 1 (d)) .....	6
2.2.5	Allows uniformity requirements to be fulfilled (see Table 1 (e)) .....	6
2.2.6	Additional points for consideration.....	6
(i)	the availability of reliable inoculum and host differential set.....	6
(ii)	quarantine regulations .....	6
(iii)	technical requirements.....	7
2.3	Developing characteristics for disease resistance.....	7
2.3.1	Qualitative characteristics.....	7
2.3.2	Quantitative characteristics .....	7
2.4	Explanations for disease resistance characteristics in Test Guidelines .....	8
2.5	The nomenclature of pathogens.....	9


5

*To summarize the current situation...*


Some slides to illustrate

**How we are describing  
the disease resistance characteristics,  
depending of their expression type.**

6



7



8

## Current situations at UPOV level :

Scale **1/9** : for QUALITATIVE (QL) characteristics

**DISCONTINUOUS** observed variability

Scale **1-2-3**: for QUANTITATIVE (QN) characteristics

**CONTINUOUS** observed variability, with a balanced scale  
with thresholds between 1 and 2, 2 and 3, thanks to well identified controls.

*And what about the «QN» char. which have been described with the scale 1/9*

*- scale which is now dedicated to QL char.*

*- Without the need/wish or the possibility to apply/manage the 1-2-3 scale?*

*And which remain managed with 2 levels of expression?*

9

## Proposal of a new UPOV **type of Expression** of characteristics

*To enable the **appropriate use of characteristics in DUS testing**,  
it is important to understand the different ways in which characteristics can be expressed.*

A new type of Expression of Characteristic have to be discussed.


We propose:

Wording to  
improve?

### **Pseudo-Quantitative Characteristics (PQN):**

It corresponds to an “almost” QUANTITATIVE characteristic  
**but with only 2 states of expression and some specificities.**

10



11

## Comparing QN / PQN definitions:

### Common points, differences

<b>“Quantitative characteristics”</b>	<b>“Pseudo-Quantitative characteristics”</b>
<p>are those where the expression covers the <b>full range of variation from one extreme to the other</b>.</p> <p>The expression can be recorded on a <b>one-dimensional, continuous</b> or discrete, <b>linear scale</b>.</p> <p>The <b>range of expressions</b> is divided into a <b>number of states</b> for the purpose of description (e.g. length of stem: very short (1), short (3), medium (5), long (7), very long (9)). The division seeks to provide, as far as is practical, an <b>even distribution across the scale</b>.</p> <p>The Test Guidelines do not specify the difference needed for distinctness<sup>2</sup>.</p> <p>The states of expression <b>should</b>, however, be meaningful for DUS assessment.</p>	<p>are those which are <b>quantitative</b>, where the expression <b>does not cover the full range of variation</b>.</p> <p>The expression can be recorded on a <b>one-dimensional, continuous but nonlinear scale</b>.</p> <p>The range of expressions is divided in <b>2 states</b> for the purpose of description, with notes 1 and 2, (e.g. Resistance to .....: <b>absent or low (1), medium or high (2)</b>). The division provides a <b>non-regular distribution across the scale</b>.</p> <p>The states of expression provide a sufficient distinctness with only 1 note difference, in the case of a condensed scale.</p> <p>The states of expression <b>are</b>, however, meaningful for DUS assessment.</p>
<p>Situation validated, but not yet updated in the definition of a <b>Quantitative characteristic (QN)</b></p> <p><sup>1</sup> or with a condensed scale: <b>absent or low (1), medium (2), high (3)</b></p> <p><sup>2</sup> The states of expression provide a sufficient distinctness with only 1 note difference, in the case of a condensed scale.</p>	

12

## In summary...

- Proposal of a **potential NEW type of expression**: *Pseudo QUANTITATIVE (PQN)*
  - **OR a revision of the QN characteristic definition** to introduce the particularities to cover the « PQN » char.
- Proposal of a **new scale**, with only **2 levels** (1= absent or low - 2= medium or high)
- These proposed evolutions don't modify the **current disease resistance test protocols**, *except an updating of the UPOV state of expression and its associated scale of notation (to replace « 1/9 » by « 1-2 »).*

13

## Questions which still remain...

Nothing new...  
Nothing easy...

- How to describe “clear difference” between borderline similar varieties in different states of expression, such as **one susceptible** and **another resistant**, both close to the cut-off point?
- How to avoid that one variety similar to the **threshold control** is **described differently by different examiners**?

The possible answers (risks limitation) are **NOT** in the **type of the scale...**  
but, in the **way to manage the description** of a QN (or PQN) characteristic.

### KEY POINTS

- A harmonised published protocol
- A panel of consensual threshold controls
- Replication of the test *if necessary*
- Use of statistical analysis (*robustness of the test*)

*In case of difficulties*

**Cooperation  
between OEs**

14



## 2 proposed annexes, for « pedagogic » purposes

### Annex I: Proposed examples to illustrate the used scales

#### QL

ToMV: 0/ tomato, TSWV/ pepper, *Passalora fulva*/ tomato

#### QN

*Meloidogyne incognita* / tomato, CMV/ cucumber

#### PQN

CGMMV / cucumber, Fom: 2 / melon, Fol: 0 and 1 / tomato

With **extracts of**  
**the current protocols (latest revisions),**  
to support the proposal.

### Annex II: How to identify and validate a threshold control?

These controls are  
the base of the decision to apply a **change**  
**between subsequent UPOV notes.**

They are carefully chosen to **manage and**  
**secure** the **cutting point** of a more or less  
continuous range of expressions.

15

## Which could be the following steps?

2024:

The understanding and possible agreement of the UPOV members.

### To be considered during the 2025 TWV:

- **Communication on a Literature Survey** covering all the disease resistance characteristics mentioned in **UPOV Test Guidelines (146 couples)**

- To illustrate the different « proposed » scales.
- a **memory aid** for listing / prioritizing the required upcoming revisions

➤ *interesting preliminary contributions* from GEVES and breeders' organisation.  
(March 2024)

16

*This prestation is the result of fruitfull exchanges and  
contributions from  
FR, NL, JP, European Union, and breeders' organizations.*

**The discussion is open.**

*Thanks a lot for your attention*